AVAV's First International LOCUST Order Adds Demand Evidence, but Control and Margin Concerns Remain

What happened

AeroVironment announced its first international purchase order for the LOCUST Laser Weapon System, a direct commercial sale valued at more than $50 million for initial systems and support. This marks the first international adoption of AV's directed-energy counter-drone capability and extends the product's demand beyond U.S. programs. The order adds modestly to funded backlog and validates the international sales channel for LOCUST, but it is small relative to the company's FY26 revenue of $1.98 billion and FY27 guidance of $2.125-$2.225 billion. The announcement does not address the company's pressing challenges: gross margin compression, SCDE segment losses, adverse ICFR opinion, and backlog conversion risk. While positive for demand narrative, it is incremental rather than transformational for the investment thesis.

Implication

Investors should view this as confirming international interest in LOCUST, but not as a solution to AVAV's core issues. The company still needs to prove revenue conversion, margin recovery, and control remediation. Until then, the WAIT rating stands, with an attractive entry near $145 and trim above $190. The order adds to backlog but does not change the risk-reward profile materially.

Thesis delta

The thesis remains largely unchanged: demand for counter-UAS is real, but execution and reporting quality need to improve. This international order slightly strengthens the demand case, but it does not address margin pressure, SCDE profitability, or internal control weaknesses. The overall WAIT rating is retained with no adjustment to valuation scenarios.